Sasanlimab
- Generic Name
- Sasanlimab
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
- Conditions
- Carcinoma, Non Small Cell LungSquamous Cell Carcinoma of the Head and Neck (SCCHN)Carcinoma, Pancreatic DuctalMalignant Melanoma
- Interventions
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 399
- Registration Number
- NCT06974734
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.
- Conditions
- Peripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin LymphomaHead and Neck Squamous Cell CarcinomaMelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 220
- Registration Number
- NCT06870487
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center., Seattle, Washington, United States
🇺🇸University of Washington Medical Center- Montlake, Seattle, Washington, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
- Conditions
- Non Small Cell Lung CancerBladder CancerRenal Cell CarcinomaHead and Neck CancerMelanomaColorectal Cancer
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT06580938
- Locations
- 🇺🇸
Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
- Conditions
- Colorectal CarcinomaSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaOvarian CarcinomaNeoplasmsNon-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5
- Registration Number
- NCT06546553
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Thomas Jefferson University Honickman Center, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Bodine Center for Radiation Therapy, Philadelphia, Pennsylvania, United States
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
- Conditions
- Advanced or Metastatic Solid TumorsColorectal CancerNon-Small Cell Lung CancerUrothelial CancerMelanoma
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT06448364
- Locations
- 🇵🇷
Hospital Oncológico Dr. Isaac González-Martinez, Rio Piedras, Puerto Rico
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇵🇷Pan American Center for Oncology Trials, LLC, Rio Piedras, Puerto Rico
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
- Conditions
- MelanomaUrothelial CarcinomaColorectal CarcinomaNeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaOvarian Carcinoma
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT06285097
- Locations
- 🇺🇸
Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota, Florida, United States
🇺🇸Corewell Health (reference non-engagement letter), Grand Rapids, Michigan, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06218069
- Locations
- 🇳🇱
Radboud University Medical Center (Radboudumc), Nijmegen, Gelderland, Netherlands
🇩🇪Eberhard Karls Universitaet Tuebingen (EKUT), Tuebingen, Germany
Ketohexokinase Inhibition in Hereditary Fructose Intolerance
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT06089265
- Locations
- 🇳🇱
Maastricht University Medical centre, Maastricht, Limburg, Netherlands
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
- Conditions
- Papillary Renal Cell Carcinoma (Prcc)Advanced Clear Cell Renal Carcinoma (Ccrcc)
- Interventions
- Drug: Palbocicilib
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT05665361
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05259397
- Locations
- 🇵🇱
Szpital Specjalistyczny im. Sw. Rodziny SPZOZ, Warszawa, Poland
🇵🇱Medical Concierge Centrum Medyczne, Warszawa, Poland
🇺🇸Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.